

PRESS RELEASE
Phase Holographic Imaging PHI AB (publ)
Lund, August 28, 2020

Publication Date of Interim Report 1

Interim report 1 for the financial year 2020/21 will be published on September 28, 2020.

ABOUT PHI

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first HoloMonitor-instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.

For additional information, please contact:

Peter Egelberg

E-mail: ir@phiab.se

Web: www.phiab.com

This information is information that Phase Holographic Imaging is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on August 28, 2020.